• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
Blog
January 21, 2021 by Global Pricing Innovations (GPI)
The Three Essentials for Opportunity Assessment

By Musa Kureshy, MSc, Business Development Manager, Global Pricing Innovations Opportunity Assessments are a vital step for in-licensing new pipeline products or making go/no-go decisions around the clinical development of early-stage assets. To be able to achieve a reliable opportunity assessment it requires…

December 3, 2020 by Global Pricing Innovations (GPI)
Spain will Require Pricing & Cost of Treatment Data for HTA submissions from Next Year: 2021, the Year of Data?

Recently Spain’s medicines regulatory bodies announced the requirement of additional “economic evaluation” data for therapeutics positioning reports (IPTs) which is the equivalent of a Health Technology Assessment process in the country. This change is part of a revolution of the overall HTA process…

November 19, 2020 by Global Pricing Innovations (GPI)
The potential impact of Biden’s presidency in the USA on the healthcare industry

By Rangaraja Konar, MBA, Business Analyst, Global Pricing Innovations Joseph Biden has been elected as the 46th President of the United States of America. He was the vice president of the states during Obama’s administration. The healthcare sector might be up to face…

November 11, 2020 by Global Pricing Innovations (GPI)
Pfizer-BioNTech alliance declare success for vaccine against COVID-19

PFIZER AND BIONTECH HAVE PRODUCED BETTER THAN EXPECTED EFFICACY RESULTS BUT WILL AWAIT FOR SAFETY DATA BEFORE FILING LATER THIS MONTH. THE PHIII INTERIM ANALYSIS FINDS VACCINE 90% EFFECTIVE WITH EUA FILING EXPECTED LATE NOVEMBER. Pfizer and BioNTech have announced positive interim Phase…

October 28, 2020 by Global Pricing Innovations (GPI)
Pharma industry concerned about recent PMPRB guidelines for IRP in Canada

Blogpost by Dimitra Sotou, MIHP, Client Solutions Lead, GPI Canada is due to adjust its international reference pricing (#IRP) basket of comparator countries come January, the 1st,  2021. The change was announced by the PMPRB in the final version of new guidelines; after five years…

October 13, 2020 by Global Pricing Innovations (GPI)
Germany’s GKV-SV targets to increase medicines’ spending ceiling by 4.6% in 2021

Blogpost created by Dimitra S. Sotou, Client Solutions Lead, Pricing & Market Access As opposed to the rest of key EU payers focusing on cost containment strategies for 2021, the German umbrella payer group GKV-Spitzenverband (GKV-SV) has announced to be targeting a +4.6%…

October 6, 2020 by Global Pricing Innovations (GPI)
White House blocks new FDA safety guidelines on COVID-19 vaccine approval

The White House has blocked stricter Food and Drug Administration (FDA) guidelines for the emergency release of the coronavirus vaccine, that would have likely prevented its approval before next month’s presidential election. The new FDA guidelines were submitted for approval to the Office…

October 2, 2020 by Global Pricing Innovations (GPI)
Medicine Manufacturers Hit Hard by Latest French Healthcare Finance Reforms

Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…

September 15, 2020 by Global Pricing Innovations (GPI)
President Trump issues expanded Executive Order Aimed at Cutting prices of prescription Medicines, prior elections

By Dimitra S. Sotou, Senior Consultant It’s been quite long since the US administration has been contemplating on techniques and mechanisms to lower prescription medicine prices covered by #Medicare . Different ideas have been brought onto the table over the past year with…

August 21, 2020 by Global Pricing Innovations (GPI)
Netherlands new IRP rule to come into effect 1st October 2020

By Musa Kureshy, Business Development Manager The impact of COVID-19 has been felt by every country and industry and the Netherlands was no exception. COVID-19 impactied drug manufacturing in China leading to it coming to a stand still and India implemented export restrictions…

August 13, 2020 by Global Pricing Innovations (GPI)
Russia: Putin granted approval to the first Coronavirus vaccine despite lack of large-scale safety & efficacy data

News summarised by Dimitra S. Sotou, Sr. Consultant, Pricing & Market Access ”Sputnik V” On Tuesday, President Vladimir Putin, announced that Russia is the first nation in the world to grant approval to a coronavirus vaccine. The approval has been granted, despite the…

August 3, 2020 by Global Pricing Innovations (GPI)
Italy launches new medicinal assessment reforms to focus on added therapeutic value

By Dimitra Sotou, Senior Consultant The Background The Italian Government has recently introduced new pricing and reimbursement rules with the central aim of making therapeutic value of prime importance in the assessment of new medicinal products conducted by AIFA. News sources confirm that…

July 29, 2020 by Global Pricing Innovations (GPI)
Trump administration releases four new executive orders, intending to reduce drug costs, before the November election

By Tom Brockbank, Senior Consultant, Pricing & Market Access Trump announced on Friday 24th July, a one-month ultimatum for drug manufacturers to offer alternative plans to reduce drug prices. This will provide manufacturers an alternative option to the stalled plan to reference drug…

July 22, 2020 by Global Pricing Innovations (GPI)
Germany’s AOK announces discount agreements for 119 drugs

By Tom Brockbank, Senior Consultant, Pricing & Market Access Germany’s major payer AOK announces discount agreements and drug manufacturer incentives to ensure a stable supply chain throughout the COVID-19 pandemic AOK has announced two-year discount agreements for 119 drugs and an obligation for…

June 25, 2020 by Global Pricing Innovations (GPI)
GPI WEBINAR: Orphan price and access forecasting – a Must for return on investment in changing times

Click HERE to Register At GPI, working daily with price and reimbursement data, we have seen a range of PMA trends across high unmet need areas such as orphan/rare diseases. Increasing pharma focus on rare diseases resulted in payers having to adapt their…

June 18, 2020 by Global Pricing Innovations (GPI)
Dexamethasone: Will recent results on COVID-19 drive up the price?

By Musa Kureshy, Business Development Manager & Tom Brockbank, Senior Consultant On Tuesday 16th of June, new research was published by scientists from Oxford University which showed that the use of Dexamethasone, a low-dose steroid treatment, on patients suffering from COVID-19 reduced deaths…

June 10, 2020 by Global Pricing Innovations (GPI)
With Beneluxa Leading the Way, Will International HTA Collaboration Become the Norm?

By Ines Dieringer, Associate Consultant at Global Pricing Innovations Belgium, the Netherlands, and Ireland are aiming to undertake a joint Health Technology Assessment (HTA) through the Beneluxa agreement of Zolgensma, Novartis’ gene therapy medication to treat spinal muscular atrophy (SMA)1. Zolgensma is a…

May 18, 2020 by Global Pricing Innovations (GPI)
ISPOR 2020: GPI presents research on novel indication sequence optimisation tool

AUTHORS: Ataide J, Murch L, Sotou D, Barkauskaite E, Patel P Beginning of the week and Day 1 for ISPOR Virtual 2020 today – We are very excited to share more results from our extensive R&D work. The infographic below provides a summary of…

May 15, 2020 by Global Pricing Innovations (GPI)
ISPOR 2020: GPI presents research on innovative framework for price forecasting

AUTHORS: Soumalevris A, Murch L, Sotou D, Barkauskaite E, Patel P Despite the worldwide impact due to COVID-19 pandemic, GPI continues to invest on extensive R&D work leading the way on how data can be leveraged to ensure our partners stay ahead of the…

April 21, 2020 by Global Pricing Innovations (GPI)
Remdesivir received EMA’s nod for COVID-19 via compassionate use programmes – What next?

By Nairuti Patel, Associate Consultant, Global Pricing Innovations Amidst the COVID-19 pandemic, EU countries (Estonia, Greece, Netherlands and Romania) requested an opinion from the Committee for Medicinal Products for Human Use (CHMP) regarding the conditions under which early access to remdesivir through compassionate…

April 16, 2020 by Global Pricing Innovations (GPI)
A Change in Priorities – How COVID-19 Has Changed the Public and Private Sector

By Ines Dieringer, Associate Consultant  The COVID-19 crisis has altered the way in which vaccines and drugs are developed and approved. In the private sector, we see unprecedented partnerships arise, while the public sector has experienced a policy shift towards a system of…

March 24, 2020 by Global Pricing Innovations (GPI)
Currently adapting to the new COVID-19 era? GPI can support you in ensuring P&MA continuity

By Dimitra Sotou, Senior Consultant, Pricing & Market Access Day 1 of official lockdown today, and increasingly more organizations around the globe are facing tighter operational restrictions due to the COVID-19 outbreak – Name it: day-to-day work, restricted travel, team meetings, cancelled conferences,…

GPI - Despite Current Uncertainty GPI's agile solutions can help ensure P&MA continuity. Get in touch to find out more!
March 20, 2020 by Global Pricing Innovations (GPI)
UPDATED – Webinar: Early Price and Access Forecasting (WFH Edition)

We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…

March 17, 2020 by Global Pricing Innovations (GPI)
GPI makes market access more efficient with pioneering partnership with Sisense-enabled analytics platform

Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers  London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…

SiSense Logo
GPI Pulse used in Spain
March 10, 2020 by Global Pricing Innovations (GPI)
Spain introduces exclusive pricing scheme for new orphan drugs. How will this affect International Reference Pricing?

Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…

March 4, 2020 by Global Pricing Innovations (GPI)
U.S. House passed an ambitious bill to lower drug prices

At the end of 2019, important legislative changes took place in the United States that could impact the country’s pharmaceutical industry over the coming years. The U.S. House of Representatives has passed the Lower Drug Costs Now Act on 12th December 2019, setting…

Lower Drug Costs
GPI in Canada
March 3, 2020 by Global Pricing Innovations (GPI)
Canada moved further to tackle high drug prices as Patented Medicines Prices Review Board (“PMPRB”) released new draft Guidelines for consultation

By Pramod Kumar Mali, Senior Business Analyst Back in August 2019, GPI reported the new regulations finalized by Canada to tackle high drug prices by making amendments to the Patented Medicines Regulations. On November 21, 2019, the Patented Medicines Prices Review Board (“PMPRB”)…

February 25, 2020 by Global Pricing Innovations (GPI)
GPI will be sponsoring the drinks reception at World Pharma Pricing Market Access & Evidence Congress 2020

Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…

GPI is the sponsor of the drinks reception at PPMA 2020. Join us on the 18th of march!
Novartis Building
February 20, 2020 by Global Pricing Innovations (GPI)
Capmatinib: The Race to Approval and Optimal Pricing

By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…

February 18, 2020 by Global Pricing Innovations (GPI)
GPI attending World Pharma Pricing, Market Access and Evidence Congress

Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…

GPI will be attending PPMA 2020. See you there!
How will Pfizer's discounted biosimilars affect Roche?
February 7, 2020 by Global Pricing Innovations (GPI)
Pfizer’s newest range of biosimilars are set to significantly undercut Roche’s ‘best-selling’ Avastin, Herceptin, and Rituxan on pricing. What will be the impact on Roche’s market share?

Pfizer has planned the launch of its biosimilar competitors in the U.S. to Roche’s cancer drugs, Avastin, Herceptin, and Rituxan, at significantly discounted prices, in comparison to the originators. Experts have noted that the launch of these medicines can lead to substantial savings…

January 22, 2020 by Global Pricing Innovations (GPI)
Global Pricing Innovations announces relocation of London Head office

London January 22nd, 2020 Today, Global Pricing Innovations (GPI), the pricing experts, are pleased to announce the relocation of its Head Office in London from 31st January 2020 to support GPI’s continued growth and expansion plans. The new facility, based in the heart…

New Head Office Location Announcement
Global Pricing Innovations Pharmaceutical Industry
January 2, 2020 by Global Pricing Innovations (GPI)
Pharmaceutical industry offers large medicine discounts in the Philippines

In recent developments, the Pharmaceutical and Healthcare Association of the Philippines (PHAP) offered substantial price reductions (up to 75%) for over 150 medicines in 36 disease categories. Drugs covered by this reduction include several oncology medicines (for breast, lung, ovarian, lymphatic cancers and…

December 6, 2019 by Global Pricing Innovations (GPI)
Pharmaceutical companies cut prices in China in exchange for inclusion on the National Reimbursement Drug List

Last week, the result of negotiations between pharma companies and China’s National Healthcare Security administration was revealed. 150 medicines were evaluated, and the outcome is as follows. Out of the 119 new medicines evaluated, 70 were accepted onto the National Reimbursement Drug List…

Pharmaceutical companies cut prices in China in exchange for inclusion on the National Reimbursement Drug List
GPI at Silicon Valley Comes to the UK Summit
November 29, 2019 by Global Pricing Innovations (GPI)
GPI at the Good Growth Summit

Preeti Patel, the CEO of GPI, was invited to the Good Growth Summit, an event designed to inspire and connect female entrepreneurs across the US and UK tech ecosystem. The Summit took part at the St James’s Palace and was hosted by Princess…

November 26, 2019 by Global Pricing Innovations (GPI)
GPI are Hiring!

We are still full steam ahead here at Global Pricing Innovations as we approach the end of 2019! Due to our continued growth & expansion, we are still actively recruiting for the below list of roles: Pricing and Market Access Lead Europe and…

GPI at Silicon Valley Comes to the UK Summit
November 22, 2019 by Global Pricing Innovations (GPI)
GPI at Silicon Valley Comes to the UK Summit

This week, GPI had the pleasure to be invited to the Silicon Valley Comes to the UK (SVC2UK) summit. SVC2UK is an annual tech conference that brings world-leading tech entrepreneurs and investors to the UK for a series of workshops, panel discussions and…

October 25, 2019 by Global Pricing Innovations (GPI)
Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs

Every three years the Federal Office of Public Health (FOPH) reviews the reimbursement conditions and, more specifically, the prices of the medicines in the list of specialities covered by the compulsory health insurance (OKP). The medicines are split into three equal groups, containing…

Switzerland has cut the price of 257 original medicines by an average of 16.3%, generating savings of 100 million francs
GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

October 21, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations is proudly attending ISPOR Europe in Copenhagen this year!

Make sure you get in touch with our Experts to find out how you can optimise your commercial potential through data analytics. For more info, contact preeti.patel@globalpricing.com

ISPOR Europe 2019, 2-6 November 2019. Copenhagen, Denmark
Novartis building
October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

October 1, 2019 by Global Pricing Innovations (GPI)
Pharma price and access pioneers, Global Pricing Innovations (GPI), continue growth with the strategic expansion to Cambridge, UK.

New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support.   London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…

What the Beneluxa Group is aiming for next
September 25, 2019 by Global Pricing Innovations (GPI)
What the Beneluxa Group is aiming for next

BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…

September 23, 2019 by Global Pricing Innovations (GPI)
With the Updated Stability Programme 2019-2022, Spanish government reinforces healthcare budget control measures

In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 27, 2019 by Global Pricing Innovations (GPI)
Italy’s drug pricing reform in trouble as Prime Minister Conte resigns

  On 1st August 2019, Italy’s State-Regions Conference approved a decree to reform the pharmaceutical pricing system of the country. A press release issued by the Ministry of Health states that the ‘Price Decree’ changes the procedures for the negotiation of the price…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 19, 2019 by Global Pricing Innovations (GPI)
The new Pricing System in Russia will lead to price decreases for many medicines

  Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…

June 10, 2019 by Global Pricing Innovations (GPI)
Renting a lifetime therapy vs. Buying a ‘one-off’ – Has the high price tag historically hindered reimbursement?

  Only recently did FDA approve Zolgensma® (by AveXis, a Novartis company), a gene therapy costing 2.1$ million, making it the most expensive medicine in the history of pharma. Zolgensma®’s most compelling feature is that it is a ‘one-off’ treatment. It utilises a…

Posts navigation

Older posts
Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121